Standardization of image quality across multiple centers by optimization of acquisition and reconstruction parameters with interim FDG-PET/CT for evaluating diffuse large B cell lymphoma
详细信息 查看全文
- 作者：Hiromitsu Daisaki (1) (3)
Ukihide Tateishi (2)
Takashi Terauchi (3)
Mitsuaki Tatsumi (4)
Kazufumi Suzuki (5)
Naoki Shimada (3)
Hiroyuki Nishida (6)
Akihiko Numata (7)
Koji Kato (7)
Koichi Akashi (7)
Mine Harada (8) (9) - 关键词：FDG ; PET/CT ; Diffuse large B cell lymphoma ; Standardization ; Multicenter study
- 刊名：Annals of Nuclear Medicine
- 出版年：2013
- 出版时间：April 2013
- 年：2013
- 卷：27
- 期：3
- 页码：225-232
- 全文大小：374KB
- 参考文献：1. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110(10):3507-6. CrossRef
2. Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol. 2002;13(9):1356-3. CrossRef
3. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica. 2006;91(4):475-1.
4. Casasnovas RO, Meignan M, Berriolo-Riedinger A, Bardet S, Julian A, Thieblemont C, et al. SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood. 2011;118(1):37-3. CrossRef
5. Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, et al. [18F]fluoro-2-deoxy-d -glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106(4):1376-1. CrossRef
6. Kasamon YL, Wahl RL, Ziessman HA, Blackford AL, Goodman SN, Fidyk CA, et al. Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning. Biol Blood Marrow Transplant. 2009;15(2):242-. CrossRef
7. Pregno P, Chiappella A, Bellò M, Botto B, Ferrero S, Franceschetti S, et al. Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood. 2012;119(9):2066-3. CrossRef
8. Zijlstra JM, Boellaard R, Hoekstra OS. Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments. Leuk Lymphoma. 2009;50(11):1748-. CrossRef
9. Kurihara C. Report of the participation in the US Society of Nuclear Medicine Clinical Trial Network Summit meeting. Clin Eval. 2010;38(3):623-.
10. Scheuermann JS, Saffer JR, Karp JS, Levering AM, Siegel BA. Qualification of PET scanners for use in multicenter cancer clinical trials: The American College of Radiology Imaging Network Experience. J Nucl Med. 2009;50(7):1187-3. CrossRef
11. http://www.jsnm.org/japanese/11-12-13. Accessed 31 Jul 2012.
12. Fukukita H, Senda M, Terauchi T, Suzuki K, Daisaki H, Matsumoto K, et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0. Ann Nucl Med. 2010;24(4):325-4. CrossRef
13. National Electrical Manufacturers Association. NEMA Standards Publication NU 2-2007: performance measurement of positron emission tomographs. Rosslyn, VA: National Electrical Manufacturers Association; 2007. - 作者单位：Hiromitsu Daisaki (1) (3)
Ukihide Tateishi (2)
Takashi Terauchi (3)
Mitsuaki Tatsumi (4)
Kazufumi Suzuki (5)
Naoki Shimada (3)
Hiroyuki Nishida (6)
Akihiko Numata (7)
Koji Kato (7)
Koichi Akashi (7)
Mine Harada (8) (9)
1. Nihon Medi-Physics Co., Ltd., Tokyo, Japan
3. Screening Technology and Development Division, Research Center for Cancer Prevention and Screening, National Cancer Center, Tokyo, Japan
2. Department of Radiology, Yokohama City University Graduate School of Medicine, Yokohama, Japan
4. Department of Radiology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
5. Department of Radiology, Dokkyo Medical University Hospital, Tochigi, Japan
6. Division of Molecular Imaging, Institute of Biomedical Research and Innovation, Kobe, Japan
7. Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
8. National Hospital Organization, Omuta Hospital, Omuta, Japan
9. Japan Study Group for Cell Therapy and Transplantation, Tochigi, Japan
文摘
Objective A multicenter trial is currently underway using FDG-PET/CT to evaluate diffuse large B cell lymphoma in Japan (JSCT NHL10). Standardization of the image quality between the participating centers is a fundamental aspect of the study. Within the framework of JSCT NHL10, standardization of the image quality was attempted by optimizing the acquisition and reconstruction conditions using mid-therapy FDG-PET/CT for diffuse large B cell lymphoma. This report describes the procedures and results of this attempt. Methods The acquisition protocols and imaging quality were initially determined at each center and again after modification. The image quality was based on performance with an 18F-filled National Electrical Manufacturers Association standards body phantom. We determined that the acquisition duration and reconstruction parameters of each scanner evaluated were in compliance with the Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0 (the Guideline) based on the results of the phantom experiments performed by the Core Laboratory. Results A total of 18 centers (19 scanners) participated in this trial. The center’s default protocol was unchanged for 9 scanners (47.4?%) and changed for 10 scanners (52.6?%). Both acquisition duration and reconstruction parameters were changed in 3 (15.8?%) of 10 scanners and the acquisition duration alone was changed in 7 (36.8?%) scanners. Also, the accuracy of the standardized uptake value (SUV) was evaluated with the acceptable level 1.0?±?0.1, resulting in readjustment and recalibration in 2 scanners (10.5?%), which were confirmed to attain the acceptable accuracy after the required readjustment. As of August 2012, 21 patients have undergone an FDG-PET/CT examination under the acquisition protocols determined by the Core Laboratory. Evaluation of the image quality using several physical parameters confirmed that the accumulated data were of sufficient quality. Conclusions Optimization of the acquisition protocol, in compliance with the guideline, was successfully achieved by the Core Laboratory in the framework of JSCT NHL10 to accumulate equivalent quality data across multiple centers. The progress of the trial was greatly facilitated by support from the Japan Society of Nuclear Medicine Working Group for Investigation of Response Evaluation Criteria in Malignant Tumors Using Standardized PET/CT (Principal Investigator: Ukihide Tateishi, MD., PhD).